In a multivariate analysis adjusted for age, sex, and race, the low-smoking group was ninefold more likely than never smokers to develop any mucocutaneous
manifestations of SLE, including a malar or discoid rash, mucosal ulcers, photosensitivity, alopecia, or scarring.
Bernard Soulier Syndrome is an inherited platelet function disorder characterized by mucocutaneous
bleeding, thrombocytopenia and giant platelaets with absence of platelet aggregation in response of Ristocetine.1 BSS with an autosomal-recessive inheritance was first described by Bernard and Soulier in 1948.2 The prevalence of BSS has been estimated around one in one million.
Many fungal infections, including chronic pulmonary aspergillosis, bone fungal infection, chronic disseminated candidiasis, chronic mucocutaneous
candidiasis and prophylaxis, require long-term antifungal therapy.
The autosomal dominant form is mainly due to mutation in STAT3 transcription factor which is characterized by immunologic abnormalities including eczematous rashes, skin abscesses, respiratory infections, elevated IgE levels, chronic mucocutaneous
candidiasis and eosinophilia and non-immunologic features including skeletal tissue, connective tissue, dental, vascular and pulmonary abnormalities1,2.
leishmaniasis: an imported infection among travellers to central and South America.
As previously described, these Behcet disease clusters included the mucocutaneous
, vascular, enthesis--arthritis--acne, and eye disease clusters (1).
Nystatin is indicated for the treatment of cutaneous or mucocutaneous
mycotic fungal infections of the skin.
manifestation, HIV, CD4, KOH.
maltophilia is the metastatic cellulitis, primary cellulitis, infected mucocutaneous
ulcers and ecthyma gangrenosum (1,8-10).
An entity recognized only recently, EBV-positive mucocutaneous
ulcer is an immunosuppression or age-related proliferation of EBV-positive atypical large B cells affecting skin or mucous sites, possibly related to local trauma or inflammation.
Patients of both sexes who suffered from mucocutaneous
adverse effects, which began after initiation of the anticancer drug.